NCT02697136 - CER-001 Therapy as a Novel Approach to Treat Genetic Orphan Diseases | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

October 31, 2018

Study Completion Date

December 21, 2018

Conditions

Familial Hypoalphalipoproteinemia

Interventions

DRUG

CER-001

Recombinant human apoA-I/phospholipid complexes

DRUG

Placebo

0.9% Sodium Chloride Injection, USP

Trial Locations (19)

Investigative Site, Salt Lake City

Investigative Site, La Louvière

Investigative Site, Vancouver

Investigative Site, Halifax

Investigative Site, London

Investigative Site, Chicoutimi

Investigative Site, Montreal

Investigative Site, Lille

Investigative Site, Montpellier

Investigative Site, Rouen

Investigative Site, Toulouse

Investigative Site, Jerusalem

Investigative Site, Tel Aviv

Investigative Site, Genoa

Investigative Site, Milan

Investigative Site, Pisa

Investigative Site, Rome

Investigative Site, Amsterdam

Investigative Site, Utrecht